1. Home
  2. CFND vs NOTV Comparison

CFND vs NOTV Comparison

Compare CFND & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$5.04

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.76

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
NOTV
Founded
N/A
1974
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
29.9M
IPO Year
2025
1997

Fundamental Metrics

Financial Performance
Metric
CFND
NOTV
Price
$5.04
$0.76
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
N/A
1.6M
Earning Date
N/A
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$513,024,000.00
Revenue This Year
N/A
$6.26
Revenue Next Year
N/A
$45.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
N/A
$0.66
52 Week High
N/A
$6.48

Technical Indicators

Market Signals
Indicator
CFND
NOTV
Relative Strength Index (RSI) N/A 35.16
Support Level N/A $0.79
Resistance Level N/A $0.86
Average True Range (ATR) 0.00 0.07
MACD 0.00 0.01
Stochastic Oscillator 0.00 3.93

Price Performance

Historical Comparison
CFND
NOTV

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: